## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

1. (currently amended) A condensation aerosol for delivery of a drug selected from the group consisting of dolasetron, granisetron and metoclopramide,

wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol, characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

- 2. (previously amended) The condensation aerosol according to Claim 1, wherein the condensation aerosol is formed at a rate greater than  $10^9$  particles per second.
- 3. (previously amended) The condensation aerosol according to Claim 2, wherein the condensation aerosol is formed at a rate greater than  $10^{10}$  particles per second.

## 4.-9. (cancelled)

- 10. (previously amended) A method of producing a drug selected from the group consisting of dolasetron, granisetron and metoclopramide in an aerosol form comprising:
- a. heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and
- b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.
- 11. (previously amended) The method according to Claim 10, wherein the condensation aerosol is formed at a rate greater than 10<sup>9</sup> particles per second.

12. (previously amended) The method according to Claim 11, wherein the condensation aerosol is formed at a rate greater than 10<sup>10</sup> particles per second.

## 13.-18. (cancelled)

- 19. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.
- 20. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.
- 21. (currently amended) The condensation aerosol according to Claim 20 1, wherein the condensation aerosol is characterized by an MMAD of about 0.2 and to about 3 microns.
- 22. (previously presented) The condensation aerosol according to Claim 1, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.
- 23. (previously presented) The condensation aerosol according to claim 22, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.
- 24. (previously presented) The condensation aerosol according to Claim 1, wherein the solid support is a metal foil.
- 25. (previously presented) The condensation aerosol according to Claim 1, wherein the drug is dolasetron.
- 26. (previously presented) The condensation aerosol according to Claim 1, wherein the drug is granisetron.
- 27. (previously presented) The condensation aerosol according to Claim 1, wherein the drug is metoclopramide.

- 28. (previously presented) The method according to Claim 10, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.
- 29. (previously presented) The method according to Claim 10, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.
- 30. (currently amended) The method according to Claim 29 10, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to about 3 microns.
- 31. (previously presented) The method according to Claim 10, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.
- 32. (previously presented) The method according to Claim 31, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.
- 33. (previously presented) The method according to Claim 10, wherein the solid support is a metal foil.
- 34. (previously presented) The method according to Claim 10, wherein the drug is dolasetron.
- 35. (previously presented) The method according to Claim 10, wherein the drug is granisetron.
- 36. (previously presented) The method according to Claim 10, wherein the drug is metoclopramide.
- 37. (previously presented) A condensation aerosol for delivery of dolasetron, wherein the condensation aerosol is formed by heating a thin layer containing dolasetron, on a solid support, to produce a vapor of dolasetron, and condensing the vapor to form a condensation

aerosol characterized by less than 5% dolasetron degradation products by weight, and an MMAD of about 0.2 to about 3 microns.

- 38. (previously presented) A condensation aerosol for delivery of granisetron, wherein the condensation aerosol is formed by heating a thin layer containing granisetron, on a solid support, to produce a vapor of granisetron, and condensing the vapor to form a condensation aerosol characterized by less than 5% granisetron degradation products by weight, and an MMAD of about 0.2 to about 3 microns.
- 39. (previously presented) A condensation aerosol for delivery of metoclopramide, wherein the condensation aerosol is formed by heating a thin layer containing metoclopramide, on a solid support, to produce a vapor of metoclopramide, and condensing the vapor to form a condensation aerosol characterized by less than 5% metoclopramide degradation products by weight, and an MMAD of about 0.2 to about 3 microns.
- 40. (previously presented) A method of producing dolasetron in an aerosol form comprising:
- a. heating a thin layer containing dolasetron, on a solid support, to produce a vapor of dolasetron, and
- b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% dolasetron degradation products by weight, and an MMAD of about 0.2 to about 3 microns.
- 41. (previously presented) A method of producing granisetron in an aerosol form comprising:
- a. heating a thin layer containing granisetron, on a solid support, to produce a vapor of granisetron, and
- b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% granisetron degradation products by weight, and an MMAD of about 0.2 to about 3 microns.

- 42. (previously presented) A method of producing metoclopramide in an aerosol form comprising:
- a. heating a thin layer containing metoclopramide, on a solid support, to produce a vapor of metoclopramide, and
- b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% metoclopramide degradation products by weight, and an MMAD of about 0.2 to about 3 microns.